​
​

Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TNDM Stock Forecast

Tandem Diabetes Care stock forecast is as follows: an average price target of $79.05 (represents a 189.14% upside from TNDM’s last price of $27.34) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

TNDM Price Target

The average price target for Tandem Diabetes Care (TNDM) is $79.05 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $160.00 to $36.00. This represents a potential 189.14% upside from TNDM's last price of $27.34.

TNDM Analyst Ratings

Buy

According to 17 Wall Street analysts, Tandem Diabetes Care's rating consensus is 'Buy'. The analyst rating breakdown for TNDM stock is 0 'Strong Buy' (0.00%), 11 'Buy' (64.71%), 5 'Hold' (29.41%), 1 'Sell' (5.88%), and 0 'Strong Sell' (0.00%).

Tandem Diabetes Care Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Jeff JohnsonRobert W. Baird$37.00$32.8712.56%35.33%
Nov 05, 2024Lee HambrightBernstein$42.00$33.1126.85%53.62%
Oct 04, 2024David RomanGoldman Sachs$46.00$39.9915.03%68.25%
Oct 02, 2024Shagun SinghRBC Capital$65.00$41.0758.27%137.75%
Aug 08, 2024William PlovanicCanaccord Genuity$57.00$37.0453.89%108.49%
Aug 05, 2024Matt MiksicBarclays$58.00$41.6739.19%112.14%
Aug 02, 2024Matt O'BrienPiper Sandler$55.00$35.2156.21%101.17%
Aug 02, 2024Jeff JohnsonRobert W. Baird$39.00$35.2110.76%42.65%
Jun 10, 2024Steven LichtmanOppenheimer$58.00$47.0323.33%112.14%
May 29, 2024Matthew BlackmanStifel Nicolaus$60.00$51.9315.55%119.46%
Row per page
Go to

The latest Tandem Diabetes Care stock forecast, released on Nov 07, 2024 by Jeff Johnson from Robert W. Baird, set a price target of $37.00, which represents a 12.56% increase from the stock price at the time of the forecast ($32.87), and a 35.33% increase from TNDM last price ($27.34).

Tandem Diabetes Care Price Target by Period

1M3M12M
# Anlaysts2418
Avg Price Target$39.50$47.50$48.94
Last Closing Price$27.34$27.34$27.34
Upside/Downside44.48%73.74%79.01%

In the current month, the average price target of Tandem Diabetes Care stock is $39.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 44.48% increase as opposed to Tandem Diabetes Care's last price of $27.34. This month's average price target is down -16.84% compared to last quarter, and down -19.29% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Bernstein-OutperformInitialise
Oct 04, 2024Goldman Sachs-NeutralInitialise
Oct 02, 2024RBC Capital-OutperformInitialise
Oct 01, 2024CitigroupBuyBuyHold
Sep 23, 2024Wells FargoBuyBuyHold
Aug 22, 2024Morgan Stanley-Equal-WeightInitialise
Aug 08, 2024Canaccord Genuity-BuyInitialise
Aug 05, 2024BarclaysOverweightOverweightHold
Aug 02, 2024Piper SandlerOverweightOverweightHold
Jul 10, 2024CitigroupBuyBuyHold
Row per page
Go to

Tandem Diabetes Care's last stock rating was published by Bernstein on Nov 05, 2024. The company Initialise its TNDM rating from "null" to "Outperform".

Tandem Diabetes Care Financial Forecast

Tandem Diabetes Care Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$281.49M$290.10M$169.38M$220.50M$204.55M$200.26M$175.91M$210.00M$179.63M$172.14M$141.04M$168.06M$123.60M$109.24M$97.93M$108.40M$94.66M
Avg Forecast$300.00M$278.05M$274.60M$248.15M$281.72M$258.80M$249.95M$221.78M$249.81M$224.14M$205.63M$174.52M$203.49M$192.76M$197.62M$170.31M$221.00M$207.60M$205.21M$168.21M$199.01M$171.37M$143.37M$121.95M$141.59M$115.33M$87.15M$84.79M$109.22M$89.14M
High Forecast$322.44M$298.84M$295.14M$266.71M$302.79M$278.16M$268.64M$226.27M$274.68M$224.35M$205.63M$174.53M$211.85M$200.65M$212.40M$183.05M$237.53M$207.60M$205.21M$168.21M$199.01M$171.37M$143.37M$121.95M$141.59M$115.33M$87.15M$84.79M$109.22M$89.14M
Low Forecast$291.64M$270.30M$266.95M$241.24M$273.87M$251.59M$242.98M$216.63M$243.35M$223.92M$205.63M$174.51M$200.16M$190.05M$192.11M$165.56M$214.84M$207.60M$205.21M$168.21M$199.01M$171.37M$143.37M$121.95M$141.59M$115.33M$87.15M$84.79M$109.22M$89.14M
# Analysts54544348126336168912778138891399955
Surprise %-------------1.46%1.47%0.99%1.00%0.99%0.98%1.05%1.06%1.05%1.20%1.16%1.19%1.07%1.25%1.15%0.99%1.06%

Tandem Diabetes Care's average Quarter revenue forecast for Dec 23 based on 6 analysts is $203.49M, with a low forecast of $200.16M, and a high forecast of $211.85M. TNDM's average Quarter revenue forecast represents a -27.71% decrease compared to the company's last Quarter revenue of $281.49M (Sep 23).

Tandem Diabetes Care EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348126336168912778138891399955
EBITDA-------------$-31.55M$-38.81M$29.68M$-17.73M$-42.77M$-8.38M$-11.77M$12.74M$10.33M$8.59M$-598.00K$24.99M$-1.77M$-23.76M$-12.21M$4.37M$-1.28M
Avg Forecast$-22.54M$-20.89M$-20.63M$-18.65M$-21.17M$-19.45M$-18.78M$-16.66M$-18.77M$-16.84M$-15.45M$-1.42M$-15.29M$-14.48M$-14.85M$-1.29M$21.44M$-9.40M$-9.29M$-1.02M$-9.01M$-7.76M$-6.49M$-807.30K$-6.41M$-5.22M$-3.95M$-7.11M$-4.95M$-4.04M
High Forecast$-21.91M$-20.31M$-20.06M$-18.13M$-20.58M$-18.90M$-18.26M$-16.28M$-18.29M$-16.83M$-15.45M$-1.14M$-15.04M$-14.28M$-14.44M$-1.03M$25.73M$-9.40M$-9.29M$-816.99K$-9.01M$-7.76M$-6.49M$-645.84K$-6.41M$-5.22M$-3.95M$-5.69M$-4.95M$-4.04M
Low Forecast$-24.23M$-22.46M$-22.18M$-20.04M$-22.75M$-20.90M$-20.19M$-17.00M$-20.64M$-16.86M$-15.45M$-1.71M$-15.92M$-15.08M$-15.96M$-1.55M$17.15M$-9.40M$-9.29M$-1.23M$-9.01M$-7.76M$-6.49M$-968.76K$-6.41M$-5.22M$-3.95M$-8.53M$-4.95M$-4.04M
Surprise %-------------2.18%2.61%-22.98%-0.83%4.55%0.90%11.52%-1.41%-1.33%-1.32%0.74%-3.90%0.34%6.02%1.72%-0.88%0.32%

8 analysts predict TNDM's average Quarter EBITDA for Jun 23 to be $-14.85M, with a high of $-14.44M and a low of $-15.96M. This is -150.03% lower than Tandem Diabetes Care's previous annual EBITDA (Mar 23) of $29.68M.

Tandem Diabetes Care Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348126336168912778138891399955
Net Income-------------$-32.96M$-35.77M$-123.87M$-15.85M$-48.97M$-15.06M$-14.71M$10.81M$5.79M$4.01M$-5.04M$17.00M$-9.41M$-27.11M$-14.87M$2.65M$-2.90M
Avg Forecast$-1.23M$-9.78M$-12.31M$-21.07M$-10.32M$-16.98M$-20.42M$-29.38M$-13.75M$-26.69M$-35.50M$-11.99M$-17.70M$-31.41M$-32.72M$-10.90M$14.72M$-4.29M$1.14M$-8.61M$13.62M$3.71M$-5.33M$-6.81M$7.76M$-7.12M$-15.58M$-8.66M$-3.05M$-12.99M
High Forecast$-1.18M$-9.42M$-11.87M$-20.30M$-9.95M$-16.36M$-19.68M$-11.63M$-11.11M$-25.72M$-34.22M$-9.59M$-11.54M$1.85M$-31.54M$-8.72M$17.66M$-4.29M$1.14M$-6.89M$13.62M$3.71M$-5.33M$-5.45M$7.76M$-7.12M$-15.58M$-6.93M$-3.05M$-12.99M
Low Forecast$-1.35M$-10.73M$-13.51M$-23.12M$-11.32M$-18.63M$-22.41M$-40.40M$-16.40M$-29.29M$-38.96M$-14.38M$-26.93M$-54.51M$-35.90M$-13.08M$11.78M$-4.29M$1.14M$-10.34M$13.62M$3.71M$-5.33M$-8.17M$7.76M$-7.12M$-15.58M$-10.39M$-3.05M$-12.99M
Surprise %-------------1.05%1.09%11.37%-1.08%11.43%-13.16%1.71%0.79%1.56%-0.75%0.74%2.19%1.32%1.74%1.72%-0.87%0.22%

Tandem Diabetes Care's average Quarter net income forecast for Mar 22 is $-8.61M, with a range of $-10.34M to $-6.89M. TNDM's average Quarter net income forecast represents a -179.70% decrease compared to the company's last Quarter net income of $10.81M (Dec 21).

Tandem Diabetes Care SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348126336168912778138891399955
SG&A-------------$79.33M$97.61M$89.81M$97.69M$84.10M$80.61M$73.27M$71.50M$64.92M$66.52M$58.56M$54.52M$50.23M$50.44M$49.72M$45.56M$44.65M
Avg Forecast$127.84M$118.49M$117.02M$105.75M$120.05M$110.29M$106.51M$94.51M$106.45M$95.51M$87.63M$139.17M$86.72M$82.14M$84.21M$126.51M$97.37M$88.47M$87.45M$100.01M$84.81M$73.03M$61.10M$79.06M$60.34M$49.15M$37.14M$28.95M$46.54M$37.99M
High Forecast$137.40M$127.35M$125.77M$113.66M$129.03M$118.54M$114.48M$96.42M$117.05M$95.61M$87.63M$167.00M$90.28M$85.50M$90.51M$151.82M$116.85M$88.47M$87.45M$120.01M$84.81M$73.03M$61.10M$94.87M$60.34M$49.15M$37.14M$34.74M$46.54M$37.99M
Low Forecast$124.28M$115.19M$113.76M$102.80M$116.71M$107.21M$103.55M$92.31M$103.70M$95.42M$87.63M$111.33M$85.29M$80.99M$81.87M$101.21M$77.90M$88.47M$87.45M$80.01M$84.81M$73.03M$61.10M$63.25M$60.34M$49.15M$37.14M$23.16M$46.54M$37.99M
Surprise %-------------0.97%1.16%0.71%1.00%0.95%0.92%0.73%0.84%0.89%1.09%0.74%0.90%1.02%1.36%1.72%0.98%1.18%

Tandem Diabetes Care's average Quarter SG&A projection for Dec 23 is $86.72M, based on 6 Wall Street analysts, with a range of $85.29M to $90.28M. The forecast indicates a 9.31% rise compared to TNDM last annual SG&A of $79.33M (Sep 23).

Tandem Diabetes Care EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348126336168912778138891399955
EPS-------------$-0.51$-0.55$-1.92$-0.25$-0.76$-0.23$-0.23$0.17$0.09$0.06$-0.08$0.27$-0.15$-0.45$-0.25$0.04$-0.05
Avg Forecast$-0.02$-0.15$-0.19$-0.32$-0.16$-0.26$-0.31$-0.45$-0.21$-0.41$-0.54$-0.76$-0.27$-0.48$-0.50$-0.54$-0.08$-0.07$0.02$-0.07$0.21$0.06$-0.08$-0.16$0.12$-0.11$-0.24$-0.17$-0.05$-0.20
High Forecast$-0.02$-0.14$-0.18$-0.31$-0.15$-0.25$-0.30$-0.18$-0.17$-0.39$-0.52$-0.73$-0.18$0.03$-0.48$-0.52$-0.08$-0.07$0.02$-0.07$0.21$0.06$-0.08$-0.16$0.12$-0.11$-0.24$-0.17$-0.05$-0.20
Low Forecast$-0.02$-0.16$-0.21$-0.35$-0.17$-0.28$-0.34$-0.62$-0.25$-0.45$-0.59$-0.83$-0.41$-0.83$-0.55$-0.59$-0.09$-0.07$0.02$-0.07$0.21$0.06$-0.08$-0.16$0.12$-0.11$-0.24$-0.17$-0.05$-0.20
Surprise %-------------1.06%1.10%3.57%3.08%11.53%-13.07%3.27%0.81%1.58%-0.73%0.50%2.26%1.37%1.88%1.47%-0.85%0.25%

According to 8 Wall Street analysts, Tandem Diabetes Care's projected average Quarter EPS for Mar 22 is $-0.07, with a low estimate of $-0.07 and a high estimate of $-0.07. This represents a -141.41% decrease compared to TNDM previous annual EPS of $0.17 (Dec 21).

Tandem Diabetes Care Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
NNOXNano-X Imaging$5.85$18.00207.69%Buy
TNDMTandem Diabetes Care$27.34$79.05189.14%Buy
ALGNAlign$223.69$421.0088.21%Buy
PACBPacific Biosciences of California$1.60$3.0087.50%Buy
INSPInspire Medical Systems$172.70$239.5538.71%Buy
MDTMedtronic$87.53$107.9123.28%Hold
ABTAbbott Laboratories$115.90$126.459.10%Buy
DXCMDexCom$75.88$81.367.22%Buy
PODDInsulet$260.12$274.005.34%Buy
PENPenumbra$237.84$224.85-5.46%Buy
SYKStryker$390.08$317.96-18.49%Buy
SWAVShockWave Medical$334.75$258.17-22.88%Hold

TNDM Forecast FAQ

Is Tandem Diabetes Care a good buy?

Yes, according to 17 Wall Street analysts, Tandem Diabetes Care (TNDM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 64.71% of TNDM's total ratings.

What is TNDM's price target?

Tandem Diabetes Care (TNDM) average price target is $79.05 with a range of $36 to $160, implying a 189.14% from its last price of $27.34. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Tandem Diabetes Care stock go up soon?

According to Wall Street analysts' prediction for TNDM stock, the company can go up by 189.14% (from the last price of $27.34 to the average price target of $79.05), up by 485.22% based on the highest stock price target, and up by 31.68% based on the lowest stock price target.

Can Tandem Diabetes Care stock reach $40?

TNDM's average twelve months analyst stock price target of $79.05 supports the claim that Tandem Diabetes Care can reach $40 in the near future.

What is Tandem Diabetes Care's current price target trend?

2 Wall Street analysts forecast a $39.5 price target for Tandem Diabetes Care (TNDM) this month, up 44.48% from its last price of $27.34. Compared to the last 3 and 12 months, the average price target increased by 73.74% and increased by 79.01%, respectively.

What are Tandem Diabetes Care's analysts' financial forecasts?

Tandem Diabetes Care's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.01B (high $1.08B, low $985.07M), average EBITDA is $-76.062M (high $-74.02M, low $-80.842M), average net income is $-77.106M (high $-57.626M, low $-92.764M), average SG&A $431.36M (high $458.47M, low $419.78M), and average EPS is $-1.177 (high $-0.879, low $-1.415). TNDM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.1B (high $1.18B, low $1.07B), average EBITDA is $-82.715M (high $-80.41M, low $-88.902M), average net income is $-44.387M (high $-42.78M, low $-48.703M), average SG&A $469.1M (high $504.18M, low $456.02M), and average EPS is $-0.677 (high $-0.653, low $-0.743).

Did the TNDM's actual financial results beat the analysts' financial forecasts?

Based on Tandem Diabetes Care's last annual report (Dec 2022), the company's revenue was $801.22M, which missed the average analysts forecast of $802.02M by -0.10%. Apple's EBITDA was $-30.77M, missing the average prediction of $1.73M by -1878.92%. The company's net income was $-94.594M, missing the average estimation of $2.96M by -3291.12%. Apple's SG&A was $335.68M, missing the average forecast of $373.3M by -10.08%. Lastly, the company's EPS was $-1.47, beating the average prediction of $-0.2 by 635.21%. In terms of the last quarterly report (Sep 2023), Tandem Diabetes Care's revenue was $281.49M, beating the average analysts' forecast of $192.76M by 46.03%. The company's EBITDA was $-31.545M, beating the average prediction of $-14.484M by 117.79%. Tandem Diabetes Care's net income was $-32.961M, beating the average estimation of $-31.415M by 4.92%. The company's SG&A was $79.33M, missing the average forecast of $82.14M by -3.43%. Lastly, the company's EPS was $-0.51, beating the average prediction of $-0.479 by 6.40%